Pennsylvania Clinical Trials

A listing of Pennsylvania clinical trials actively recruiting patient volunteers.

Now enjoying a moment in the sun thanks to the breakout popularity of Flyers mascot Gritty, Pennsylvania's capital Philadelphia has long been known as "The City of Brotherly Love" and home of the first public library in the United States. Founding Father Benjamin Franklin, a prolific inventor and author, spent much of his life in Philadelphia and left an indelible mark there. The U.S. Declaration of Independence, U.S Constitution, and Gettysburg Address were all written in Pennsylvania. The University of Pennsylvania is one of America's leading colleges, and UPMC Presbyterian, associated with the University of Pittsburgh, is the largest hospital.

Filter by Condition
3381 trials found

Liver Cell Transplant for Phenylketonuria

NCT01465100

Human phenylketonuria (PKU) results from phenylalanine hydroxylase (PAH) deficiency, and represents one of the most common and extensively studied single-gene Mendelian disorders in humans. Unfortunately, optimum clinical outcome demands lifelong dietary restriction through adherence to an unpalatable and expensive artificial diet. Challenges in maintaining traditional therapy lead to increasing phenylalanine (Phe) levels in patients as they approach adulthood with an incumbent severe burden of ...

Conditions: Phenylketonuria
Phase: Phase 1/2

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

NCT01436968

The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. ProstAtak has shown synergy with radiation without added toxicity and lower than expected recurrence rates in pre ...

Conditions: Prostate Cancer

Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency

NCT01379469

The primary objective is to determine if the medication Carbamazepine, can be used as a therapy for patients with severe liver disease due to Alpha-1-Antitrypsin Deficiency .

Conditions: Alpha-1-antitrypsin Deficiency, Liver Cirrhosis

Stereotactic Body Radiation Therapy (SBRT) for Liver Mets

NCT01360606

This is a phase I dose escalation study. Dose escalation will be via the traditional "up and down" scheme. SBRT: Patients will receive one of the following radiation regimens: 50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period. 60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period. 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period.

Conditions: Liver Metastases
Phase: Not Applicable

An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

NCT01357668

The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.

Conditions: Juvenile Idiopathic Arthritis

Genes and Environment in Multiple Sclerosis

NCT01353547

The purpose of the research study is to identify the genetic, environmental and immune profiles that may increase a person's risk of developing multiple sclerosis (MS). While MS is not a disease caused by a single variation in genetic material (DNA), a single environmental factor, or a single malfunction in immune cells, there are genetic alterations, environmental exposures and immunologic factors that make the development of MS more likely. Obtaining information about who is at risk for MS wil ...

Conditions: Multiple Sclerosis

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

NCT01351545

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

Conditions: Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Automimmune Diseases, Severe Aplastic Anemia

S0820, Adenoma and Second Primary Prevention Trial

NCT01349881

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.

Conditions: Colorectal Neoplasms

TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma

NCT01349075

TheraSphere is a medical device containing yttrium-90 (Y-90) a radioactive material that has been used to treat liver tumors. When Y-90 is put into very tiny glass beads (TheraSphere), it can be injected into the liver through a blood vessel. This allows a large local dose of radiation to be delivered to the tumor with less risk of toxic effects from radiation to other parts of the body or to healthy liver tissue.

Conditions: Hepatocellular Carcinoma

A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors

NCT01349101

It is hypothesized that engraftment when administering cyclophosphamide post the stem cell infusion will increase, the incidence of graft versus host disease (GVHD) and day 100 mortality will decrease, and the use of cyclophosphamide post stem cell infusion with alternative donors will be as safe and as effective as traditional matched transplants.

Conditions: Hematological Malignancies

Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation

NCT01345539

The purpose of this study is to evaluate feasibility of radiosurgery for all metastatic sites for patients presenting with oligometastatic disease.

Conditions: Oligometastatic Disease

Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women

NCT01310023

SMARTT will estimate the incidence of conditions and diagnoses potentially related to in utero exposure to antiretroviral therapy and/or exposure in the first two months of life among children born of HIV-infected mothers.

Conditions: Antiretroviral Toxicity